Hematopoietic growth factors in autologous bone marrow transplantation.


The availability of recombinant human hematopoietic growth factors (rhHGFs) for clinical use has the potential to significantly decrease the morbidity and cost of autologous bone marrow transplantation (ABMT) and to make this therapeutic modality available to a broader patient population. Three rhHGFs currently have Food and Drug Administration-approved… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.